Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chul S Ha

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Cancer|December 6, 2002
An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin diseaseGregory M Chronowski, Richard B Wilder, Susan L Tucker, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2002
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapyGregory M Chronowski, Richard B Wilder, Susan L Tucker, et al.
Cancer|March 26, 2011
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapyValerie Reed, Jatin Shah, L Jeffery Medeiros, et al.
Blood|June 5, 2004
Outcome with the hyper-CVAD regimens in lymphoblastic lymphomaDeborah A Thomas, Susan O'Brien, Jorge Cortes, et al.
American Journal of Clinical Oncology|February 6, 2004
Second malignancies after chemotherapy and radiotherapy for Hodgkin diseaseGregory M Chronowski, Richard B Wilder, Larry B Levy, et al.
Cancer|August 28, 2003
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapyBouthaina S Dabaja, Peter McLaughlin, Chul S Ha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphomaJohn F Seymour, Barbara Pro, Lillian M Fuller, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) LymphomaPenny Fang, Jillian R Gunther, Chelsea C Pinnix, et al.
Oncology (Williston Park, N.Y.)|October 19, 2013
ACR Appropriateness Criteria: Localized nodal indolent lymphomaBradford S Hoppe, David C Hodgson, Ranjana Advani, et al.
Molecular Oncology|October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle studyChul S Ha, Joel E Michalek, Richard Elledge, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Cancer|December 6, 2002
An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin diseaseGregory M Chronowski, Richard B Wilder, Susan L Tucker, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2002
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapyGregory M Chronowski, Richard B Wilder, Susan L Tucker, et al.
Cancer|March 26, 2011
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapyValerie Reed, Jatin Shah, L Jeffery Medeiros, et al.
Blood|June 5, 2004
Outcome with the hyper-CVAD regimens in lymphoblastic lymphomaDeborah A Thomas, Susan O'Brien, Jorge Cortes, et al.
American Journal of Clinical Oncology|February 6, 2004
Second malignancies after chemotherapy and radiotherapy for Hodgkin diseaseGregory M Chronowski, Richard B Wilder, Larry B Levy, et al.
Cancer|August 28, 2003
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapyBouthaina S Dabaja, Peter McLaughlin, Chul S Ha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphomaJohn F Seymour, Barbara Pro, Lillian M Fuller, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) LymphomaPenny Fang, Jillian R Gunther, Chelsea C Pinnix, et al.
Oncology (Williston Park, N.Y.)|October 19, 2013
ACR Appropriateness Criteria: Localized nodal indolent lymphomaBradford S Hoppe, David C Hodgson, Ranjana Advani, et al.
Molecular Oncology|October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle studyChul S Ha, Joel E Michalek, Richard Elledge, et al.
Pageof 7